Showing results (41-50 of 731) with videos related to

Sort By:
Pageof 74
Electrophoresis|November 9, 2007
Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphomaMarc Weinkauf, Maximilian Christopeit, Wolfgang Hiddemann, et al.
Lancet (London, England)|April 13, 2024
B-cell non-Hodgkin lymphomasElisabeth Silkenstedt, Gilles Salles, Elias Campo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?Martin Dreyling, Simone Ferrero, Niklas Vogt, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 7, 2026
Modern Management of Mantle Cell LymphomaTobias Tix, Anita Kumar, Toby A Eyre, et al.
Leukemia & Lymphoma|June 18, 2014
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009Christian Schmidt, Guenter Fingerle-Rowson, Angelika Boehme, et al.
Critical Reviews in Oncology/Hematology|June 11, 2011
Mantle cell lymphomaSergio Cortelazzo, Maurilio Ponzoni, Andrés J M Ferreri, et al.
BMC Cancer|June 27, 2013
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trialMathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, et al.
Leukemia & Lymphoma|June 19, 2018
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trialsRishu Agarwal, Mark A Dawson, Martin Dreyling, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Blood|August 30, 2011
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaRobert Griffiths, Joseph Mikhael, Michelle Gleeson, et al.
Pageof 74